



Still got family.  
Still got focus.  
Still got fight.

Still  
got  
it.

I'm David, and I don't let Parkinson's define me. That's because I've been on RYTARY since 2016, which gives me less "off" time and more time to do what I love.

If "off" time is starting to define your time, **RYTARY** may be able to help.

**INDICATION** RYTARY (carbidopa and levodopa) extended-release capsules is a prescription medication that contains a combination of carbidopa and levodopa for the treatment of Parkinson's disease, Parkinson's disease caused by infection or inflammation of the brain, or Parkinson's disease like symptoms that may result from carbon monoxide or manganese poisoning.

**IMPORTANT SAFETY INFORMATION** Do not take RYTARY with antidepressant medications known as nonselective monoamine oxidase (MAO) inhibitors because taking these two drugs within two weeks of each other can result in high blood pressure.

Please see Important Safety Information on pages 16 and 17 and accompanying [full Prescribing Information](#).


**RYTARY**  
(carbidopa and levodopa)  
EXTENDED-RELEASE CAPSULES  
23.75 mg/95 mg • 36.25 mg/145 mg  
48.75 mg/195 mg • 61.25 mg/245 mg

# You may have Parkinson's, but you're still you.

We're all defined by something—our character, a career, or even a cause. It's what we're known for, what keeps us going, and what makes us who we are.

Whatever it is that defines or drives you, don't let "off" time get in the way. Use the information found in this brochure to advocate for yourself, ask questions, and be honest about what you need from treatment. In doing so, you may be able to enjoy more of what makes you, you.

Please see Important Safety Information on pages 16 and 17 and accompanying [full Prescribing Information](#).



“ I fought for justice as a lawyer for many years, and now I fight against Parkinson's. ”

**RYTARY**<sup>®</sup>  
(carbidopa and levodopa)

EXTENDED-RELEASE CAPSULES  
23.75 mg/95 mg • 36.25 mg/145 mg  
48.75 mg/195 mg • 61.25 mg/245 mg

The individuals appearing in this piece were sponsored by Amneal Pharmaceuticals. Your experience and results may vary.

# Listen to your body. And then speak on its behalf.

When it comes to managing Parkinson's, it can be helpful to listen to your body throughout the day—particularly when it comes to your symptoms. For example, by tracking your “on” time and your “off” time and then talking honestly with your healthcare provider about your experiences.

“On” time – when your symptoms are under control

“Off” time – when you are experiencing symptoms

**If you're experiencing “off” time, you're not alone.  
One survey found that among people with Parkinson's:**



experience  
at least 1  
“off” episode  
each day.



experience 2  
or more hours  
of “off” time  
each day.



said that “off”  
time affected  
their daily  
activities.

Please see Important Safety Information on pages 16 and 17 and accompanying [full Prescribing Information](#).

# What is your “off” time trying to tell you?

Given the disruptions that “off” time can cause, it may also be worth noting what kind of “off” time you're experiencing. After all, the more detail you can give your healthcare provider, the more able he or she will be to help you find a medication that fits your needs.

- **Partial “on”** happens when there is a partial effect of your medication, and may feel like you are between “off” and “on”
- **Dose failure** happens when your dose of medication does not stop the “off” episode
- **Early morning “off”** happens when you feel poor control of symptoms when you wake up
- **Wearing “off”** happens when the benefits of your medicine lessen before you take your next dose
- **Unpredictable “off”** happens unexpectedly, even if you've taken your medicine exactly as you are supposed to

“ I took several CD/LD medications after I was diagnosed. I experienced about 7 or 8 hours of ‘off’ time each day with them. ”

Individual results may vary.




# What causes “off” time?

The combination of carbidopa (CD) and levodopa (LD) is a mainstay of Parkinson’s treatment, with the immediate-release formulation of CD/LD being among the most commonly prescribed. However, the fact that it’s immediate release means that, while it works quickly, it may not work for very long.

Also, once people have been taking it for a while, they begin to fluctuate between “on” and “off” periods. This is because the window of time that the medication can be effective without causing side effects (like dyskinesia) is narrowing, as shown in the visual below.


## Over time, “on” time can be more difficult to achieve



## IMPORTANT SAFETY INFORMATION

Taking RYTARY may result in falling asleep while engaged in normal activities, even without warning and as late as one year after starting RYTARY. This may affect your ability to drive or operate machinery. Do not do anything that requires alertness until you know how RYTARY affects you.

# If you’re having “off” time, RYTARY may be able to help.



“ As my ‘off’ time became longer in duration and more severe, my healthcare provider suggested that I try RYTARY. She said if I tolerated it well, RYTARY may allow one extra hour of ‘on’ time compared with my previous treatment. I think anyone with Parkinson’s could understand how valuable that sounded.”

Individual results may vary.

Please see Important Safety Information on pages 16 and 17 and accompanying [full Prescribing Information](#).

**RYTARY**  
(carbidopa and levodopa)  
EXTENDED-RELEASE CAPSULES  
23.75 mg/95 mg • 36.25 mg/145 mg  
48.75 mg/195 mg • 61.25 mg/245 mg


# You're unique. And so is RYTARY.

While RYTARY also contains a combination of CD and LD, it is uniquely formulated to be both immediate *and* extended release.

Inside each RYTARY capsule is a unique combination of time-release beads.

- **1/3 are immediate release**, which allows RYTARY to start working quickly
- **2/3 are extended release**, which, when combined with the other beads, allows RYTARY to work for up to 4–5 hours

Together, this may reduce the amount of “off” time you experience each day.




## IMPORTANT SAFETY INFORMATION

Tell your healthcare provider if you have any heart conditions, especially if you have had a heart attack or irregular heartbeats; if you experience hallucinations or abnormal thoughts and behaviors (such as excessive suspicion, believing things that are not real, confusion, agitation, aggressive behavior, and disorganized thinking), if you have intense urges to gamble, increased sexual urges, other intense urges, and the inability to control those urges; if abnormal involuntary movements appear or get worse during treatment with RYTARY; or if you have ever had a peptic ulcer or glaucoma.

# RYTARY stays with you longer.

As discussed earlier, LD-based treatments often cause fluctuations between periods of “on” time and “off” time because they aren’t able to sustain steady levels of LD.

However, when a clinical study compared the way RYTARY behaves in the body to the way other CD/LD medications behave, it found that RYTARY was able to keep LD levels steady for longer than these other medications. The results from this study are depicted in the visual below.



Please see Important Safety Information on pages 16 and 17 and accompanying [full Prescribing Information](#).

**RYTARY**  
(carbidopa and levodopa)  
EXTENDED-RELEASE CAPSULES  
23.75 mg/95 mg • 36.25 mg/145 mg  
48.75 mg/195 mg • 61.25 mg/245 mg

# Let RYTARY help the real you shine through.

In another clinical study, the effectiveness of RYTARY was compared to immediate-release (IR) CD/LD in people with advanced Parkinson's disease. In this study, RYTARY demonstrated:

## 2X reduction in "off" time during waking hours

- 13.1% reduction vs 6.2% reduction with IR CD/LD
- 2.2 hours vs 1 hour with IR CD/LD\*

## 2X increase in "on" time without troublesome dyskinesia

- 1.8 hours vs 0.8 hours with IR CD/LD\*


## Better movement control

- Improved performance of motor functions and activities of daily living

\*Total "off" time during waking hours and total "on" time without troublesome dyskinesia were secondary measures in the study.

### IMPORTANT SAFETY INFORMATION

The most common side effects that may occur with RYTARY include nausea, dizziness, headache, sleeplessness, abnormal dreams, dry mouth, abnormal involuntary movements, anxiety, constipation, vomiting, and low blood pressure upon rising.



“ RYTARY definitely gives me more ‘on’ time, so it’s been a great choice for me. ”

Individual results may vary.

Please see Important Safety Information on pages 16 and 17 and accompanying [full Prescribing Information](#).


**RYTARY**<sup>®</sup>  
(carbidopa and levodopa)  
EXTENDED-RELEASE CAPSULES  
23.75 mg/95 mg • 36.25 mg/145 mg  
48.75 mg/195 mg • 61.25 mg/245 mg

## Let your voice be heard.

A primary goal of treatment is to find a medication that reduces your “off” time so that you can get back to doing more of what you enjoy. But in order to do that, you have to be open and honest about how you’re feeling—with yourself, with your family, and especially with your healthcare provider.

Nobody knows your body better than you. Which means that, ultimately, you’re the only one who can truly determine whether your Parkinson’s treatment plan is working. That’s why advocating for yourself is so important.

“ We all have two choices when it comes to Parkinson’s. We can resign ourselves to it and give up, or we can fight back and push through it...I’ve been a fighter all my life, so every morning I wake up and choose to fight Parkinson’s for another day. I hope you choose to fight, too. ”



Please see Important Safety Information on pages 16 and 17 and accompanying [full Prescribing Information](#).

**RYTARY**<sup>®</sup>  
 (carbidopa and levodopa)  
 EXTENDED-RELEASE CAPSULES  
 23.75 mg/95 mg • 36.25 mg/145 mg  
 48.75 mg/195 mg • 61.25 mg/245 mg

## Track your “off” time.

Tracking your “off” time (ie, when you experience motor symptoms, such as tremors, rigidity, or trouble walking) can help you have a productive conversation with your healthcare provider. Each time you experience an “off” episode, note its start time and end time in the chart below and share it at your next appointment.

“OFF” EPISODE:		1	2	3	4	5	6
Day 1	Start						
	End						
Day 2	Start						
	End						
Day 3	Start						
	End						
Day 4	Start						
	End						
Day 5	Start						
	End						
Day 6	Start						
	End						
Day 7	Start						
	End						

# Could RYTARY be right for you?

Once you've finished tracking your "off" time, ask yourself the following questions:

	Yes	No	Not Sure
Is it hard to predict how my day will go because of "off" time?			
Is Parkinson's getting in the way of making plans or doing my everyday activities?			
Could I benefit from a treatment option that lasts longer than other CD/LD treatments?			

## IMPORTANT SAFETY INFORMATION

Some patients taking RYTARY have experienced suicidal thoughts or have attempted suicide. Tell your healthcare provider if you have thoughts of suicide or have attempted suicide.

Please see Important Safety Information on pages 16 and 17 and accompanying [full Prescribing Information](#).

**RYTARY**  
 (carbidopa and levodopa)  
 EXTENDED-RELEASE CAPSULES  
 23.75 mg/95 mg • 36.25 mg/145 mg  
 48.75 mg/195 mg • 61.25 mg/245 mg

## Get the support you need with

**MYRYTARY**  
 PATIENT SUPPORT PROGRAM

Managing Parkinson's disease isn't something you should have to do alone.

That's why we've developed the MyRYTARY Patient Support Program. Offering a range of resources—including information on financial assistance—the program is designed to make it easier for you to access RYTARY.

Everyone who enrolls is assigned a dedicated case manager who can:



Perform a benefits investigation to help you understand your specific coverage and figure out how much RYTARY is likely to cost.



Tell you about affordability options you may be eligible for, such as the RYTARY Co-Pay Savings Card.



To learn more about MyRYTARY, call **1-844-467-2928** (Monday through Friday, 8:00 AM – 8:00 PM ET), or visit **MyRYTARY.com**.

## INDICATION

RYTARY (carbidopa and levodopa) extended-release capsules is a prescription medication that contains a combination of carbidopa and levodopa for the treatment of Parkinson's disease, Parkinson's disease caused by infection or inflammation of the brain, or Parkinson's disease like symptoms that may result from carbon monoxide or manganese poisoning.

## IMPORTANT SAFETY INFORMATION

Do not take RYTARY with antidepressant medications known as nonselective monoamine oxidase (MAO) inhibitors because taking these two drugs within two weeks of each other can result in high blood pressure.

Taking RYTARY may result in falling asleep while engaged in normal activities, even without warning and as late as one year after starting RYTARY. This may affect your ability to drive or operate machinery. Do not do anything that requires alertness until you know how RYTARY affects you.

Tell your healthcare provider if you have any heart conditions, especially if you have had a heart attack or irregular heartbeats; if you experience hallucinations or abnormal thoughts and behaviors (such as excessive suspicion, believing things that are not real, confusion, agitation, aggressive behavior, and disorganized thinking), if you have intense urges to gamble, increased sexual urges, other intense urges, and the inability to control those urges; if abnormal involuntary movements appear or get worse during treatment with RYTARY; or if you have ever had a peptic ulcer or glaucoma.

The most common side effects that may occur with RYTARY include nausea, dizziness, headache, sleeplessness, abnormal dreams, dry mouth, abnormal involuntary movements, anxiety, constipation, vomiting, and low blood pressure upon rising.

Some patients taking RYTARY have experienced suicidal thoughts or have attempted suicide. Tell your healthcare provider if you have thoughts of suicide or have attempted suicide.

Notify your healthcare provider if you become pregnant or intend to become pregnant during therapy or if you intend to breast-feed or are breast-feeding an infant.

Talk to your healthcare provider before you lower the dose or stop taking RYTARY, as this may result in serious side effects. Call your healthcare provider immediately if you develop withdrawal symptoms such as fever, confusion, or severe muscle stiffness.

Take RYTARY as instructed. You may take RYTARY with or without food; however, taking RYTARY with food may decrease or delay its effect. For this reason, consider taking the first dose of the day about 1 to 2 hours before eating. Swallow RYTARY whole; do not chew, divide, or crush. If you have difficulty swallowing the capsule, twist apart both halves and sprinkle the entire contents of both halves of the capsule on a small amount of applesauce (1 to 2 tablespoons). Consume the mixture immediately. Do not store the drug/food mixture for future use.

Note: This information is intended to aid in the safe and effective use of RYTARY. It is not a disclosure of all possible adverse or intended effects. Tell your healthcare provider if you have any side effects while taking RYTARY. He or she can make adjustments that may reduce these effects.

**To report SUSPECTED ADVERSE REACTIONS, contact Amneal Specialty, a division of Amneal Pharmaceuticals LLC at 1-877-835-5472 or the FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

Please see accompanying [full Prescribing Information](#). For more information go to [RYTARY.com](http://RYTARY.com) and/or talk to your healthcare provider.

**RYTARY**<sup>®</sup>  
(carbidopa and levodopa)  
EXTENDED-RELEASE CAPSULES  
23.75 mg/95 mg • 36.25 mg/145 mg  
48.75 mg/195 mg • 61.25 mg/245 mg



## Like David's story? Meet Nancy. She's been on RYTARY since 2018.

To watch her real RYTARY story—and stories from others just like her—simply open the camera app on your smartphone and hover it over the QR code to the right or visit [RYTARY.com](https://www.RYTARY.com).



Please see Important Safety Information on pages 16 and 17 and accompanying [full Prescribing Information](#).



RYTARY® and MyRYTARY® are registered trademarks of Amneal Pharmaceuticals LLC.  
© 2020 Amneal Pharmaceuticals LLC. Distributed by Amneal Specialty, a division of Amneal Pharmaceuticals LLC.  
All rights reserved. Printed in USA. PP-PAT-RYT-US-0233 06/2020

**RYTARY**<sup>®</sup>  
(carbidopa and levodopa)

EXTENDED-RELEASE CAPSULES

23.75 mg/95 mg • 36.25 mg/145 mg  
48.75 mg/195 mg • 61.25 mg/245 mg